Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




New Hematology Analyzer Brings High-Standard Reticulocyte Analysis to a Compact Platform

By LabMedica International staff writers
Posted on 03 Mar 2014
A new, reliable, easy-to-use hematology analyzer with integrated PC eliminates manual methods to enhance laboratory productivity while maintaining standardization.

Horiba Medical division of Horiba UK (Northhampton, UK) now offers the new "Pentra XLR compact 5 part DIFF" hematology analyzer, incorporating full reticulocyte parameters to facilitate the investigation and diagnosis of hemopoiesis and anemia. More...
As the latest addition to the Pentra family, the XLR brings Horiba’s gold standard reticulocyte technology with STAT capabilities to a smaller platform. This makes it well suited for space-restricted laboratories or those with a smaller workload, without compromising on quality.

The new, reliable, easy-to-use analyzer with integrated PC eliminates manual methods to enhance laboratory productivity and ensure standardization of reticulocyte count. The Pentra XLR’s large capacity autoloader and ability to process 80 samples per hour, combined with auto rerun, Customized Dilution Ratio (CDR) and automatic validation, all enable a hands-off approach. Users can thus dedicate valuable time to results analysis and more specialised needs.

Providing a high degree of flexibility, the new Pentra XLR has a microsampling system requiring only 53 µl of blood for FBC and 35 µl for full reticulocyte analysis, making it well suited for pediatric or other small samples. The reticulocyte channel utilizes Thiazole Orange technology, providing a full maturity profile in addition to a highly accurate reticulocyte count. It is also compatible with ABX Pentra ML data management, facilitating simple integration into existing systems.
The new Pentra XLR is built on the same proven reticulocyte technology as Horiba’s higher throughput Pentra analyzers, ensuring quality and full compatibility of results and reagents. With three quality control levels for all parameters, this robust and reliable platform also provides complete data traceability on-board and integrated validation, thus enhancing peace of mind also for the user.

“The Pentra XLR enhances laboratory productivity, flexibility and quality, adding value to any hematology laboratory,” said Cleve Wright, Horiba UK; “By incorporating full reticulocyte analytical capabilities, the Pentra XLR delivers high quality detailed analysis for highly accurate patient diagnosis on a compact platform.”

Related Links:

Horiba Medical



New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Silver Member
Rapid Test Reader
DIA5000
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.